Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Monday 26.02.2024 at 12:00 PM CET
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12Q1/70

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20240061002PATHOGEN TESTING SYSTEMS AND METHODS OF USE THEREOF
US 22.02.2024
Int.Class G01N 35/00
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
35Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/-G01N33/148; Handling materials therefor
Appl.No 18270438 Applicant Salus Discovery, LLC Inventor Peter James Dailey

Provided herein are mobile systems for sample processing. In some aspects, provided herein are mobile systems for sample processing and methods of use thereof for detection of pathogens in biological samples.

2.20240060136METHODS FOR DETECTING AND PREDICTING GRADE 3 CERVICAL EPITHELIAL NEOPLASIA (CIN3) AND/OR CANCER
US 22.02.2024
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
Appl.No 18009957 Applicant UCL Business Ltd Inventor Martin Widschwendter

The present invention relates to assays for predicting the presence, absence or development of CIN3 and/or cancer, particularly cervical or endometrial cancer, most preferably cervical cancer, in an individual, particularly cervical and endometrial cancer, by determining the methylation status of certain CpGs in a population of DNA molecules in a sample which has been taken from the individual, deriving an index value based on the methylation status of the certain CpGs, and predicting the presence, absence or development of CIN3 and/or cancer, particularly cervical or endometrial cancer, most preferably cervical cancer, in the individual based on the cancer index value. The invention further relates to a method of treating and/or prevention of cancer in an individual, particularly cervical and endometrial cancer, the method comprising assessing the presence, absence or development of CIN3 and/In or cancer, particularly cervical or endometrial cancer, most preferably cervical cancer, in an individual by performing the assays of the invention, followed by administering one or more therapeutic treatments or measures to the individual based on the assessment. The invention further provides a method of monitoring the CIN3 and/or cancer status of an individual according to changes in the individual's cancer index value over the course of time. The invention further relates to arrays which are suitable for performing the assays of the invention.

3.20240060131METHOD FOR IDENTIFYING AND/OR REGULATING SENESCENCE
US 22.02.2024
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
Appl.No 18150917 Applicant INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES Inventor Guanghui LIU

A method using an endogenous retrovirus (ERV) as a biomarker for detecting a degree of aging of an object or a cell, tissue or organ or isolated cell thereof. A method using an ERV as a target for treating, preventing or delaying aging of the subject or a cell, tissue or organ or isolated cell thereof.

4.WO/2024/040246POINT-OF-CARE ON-CHIP IGRA DEVICE AND METHOD FOR MEASURING SPECIFIC T CELL ACTIVATION
WO 22.02.2024
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/US2023/072511 Applicant THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND Inventor HU, Ye, Tony
Method and device for detecting SARS-CoV-2 specific T-Cell interferon-gamma activation is described. By using a microfluidic chip to allow ELISpot interferon gamma release assays (IGRA) be performed using a small amount of fingerstick whole blood sample, fast results can be provided with minimal amount of blood sample.
5.2024022080ポリペプチド、抗E型肝炎ウイルス抗体の検出方法、抗E型肝炎ウイルス抗体及びE型肝炎ウイルスの同時検出方法、及びキット
JP 16.02.2024
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
Appl.No 2022125417 Applicant 株式会社先端生命科学研究所 Inventor 槇 昇
【課題】抗E型肝炎ウイルス抗体の検出、特に、抗E型肝炎ウイルス抗体及びE型肝炎ウイルスの同時検出を十分に高感度で行うことが可能なポリペプチドを提供すること。
【解決手段】下記(a)及び(b)からなる群から選択されてよい、少なくとも1種のポリペプチド。
(a)それぞれ配列が異なる、ある特定の4種のアミノ酸配列のうちのいずれかに記載のアミノ酸配列の第41番目のアスパラギン酸が他の任意のアミノ酸に置換された置換アミノ酸であるアミノ酸配列を含むポリペプチド
(b)前記ある特定の4種の配列番号のうちのいずれかに記載のアミノ酸配列において1若しくは複数個が置換、欠失、挿入及び/又は付加されたアミノ酸配列であり、かつ、その配列番号に記載のアミノ酸配列の第41番目のアスパラギン酸に対応するアミノ酸が、アスパラギン酸以外の任意のアミノ酸に置換された置換アミノ酸であるアミノ酸配列を含むポリペプチド
【選択図】なし
6.3138815Détermination de la nature virale ou bactérienne d’une infection
FR 16.02.2024
Int.Class C12Q 1/6888
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6888for detection or identification of organisms
Appl.No 2208298 Applicant BIOMERIEUX Inventor MOMMERT MARINE
La présente invention a pour objet des méthodes in vitro ou ex vivo et des kits pour déterminer à partir d’un échantillon biologique d’un sujet la nature d’une infection, à savoir virale ou bactérienne, par l’intermédiaire de l’identification de la variation du niveau d’expression de plusieurs biomarqueurs. En particulier, la méthode comprenant les étapes de (a) mesure de l’expression d’au moins deux gènes choisis parmi les gènes cibles SIGLEC1, ISG15, HERC6, SLC1A2, IL1R2, FAM20A, OLAH, RETN et MMP8, de (b) comparaison des expressions mesurées à l’étape (a) avec des valeurs d’expression de références desdits gènes cibles, et de (c) conclusion quant à la nature virale ou bactérienne de l’infection sur la base des résultats de comparaison.
7.WO/2024/036192COMPOSITIONS AND METHODS FOR ASSESSING THE SEVERITY OF AND TREATING COVID-19
WO 15.02.2024
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
Appl.No PCT/US2023/071902 Applicant THE JOHNS HOPKINS UNIVERSITY Inventor JOHNS, Roger
The present invention relates to the field of virology. More specifically, the present invention provides compositions and methods for assessing the severity of and treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or COVID-19. In particular embodiments, a method for treating COVID-19 in a patient comprises the step of administering to the patient an isolated, recombinant antibody or antigen-binding fragment thereof that binds human Resistin.
8.20240052436CRISPR-BASED SARS-COV-2 DETECTION
US 15.02.2024
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
Appl.No 18009832 Applicant SHERLOCK BIOSCIENCES Inventor Xiang Li

The present disclosure provides methods and compositions for the detection of SARS-CoV-2 by CRISPR/Cas collateral RNAse activity.

9.WO/2024/036134DEFENSIN PROTEINS FOR INFECTION ASSESSMENT
WO 15.02.2024
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
Appl.No PCT/US2023/071821 Applicant SRI INTERNATIONAL Inventor SHALER, Thomas A.
Embodiments are directed to an apparatus comprising a support to receive a biological sample and a plurality of reagents. The plurality of reagents can include a plurality of first agents configured to bind to a pre-active peptide portion of a defensin protein in the biological sample, a plurality of second agents that exhibit a detectable signal and configured to bind to at least one of the pre-active peptide portion or respective ones of the plurality of first agents. Wherein binding between different respective ones of the plurality of first agents, the pre-active peptide portion, and the plurality of second agents on the support is configured to generate the detectable signal which is indicative of an expression level of the pre-active peptide portion in the biological sample.
10.WO/2024/033450BIOLOGICAL TEST SAMPLING KIT
WO 15.02.2024
Int.Class C12Q 1/04
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
02involving viable microorganisms
04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
Appl.No PCT/EP2023/072116 Applicant HEMODX AS Inventor SHARMA, Praveen
The present invention relates to methods and kits for the collection, preservation and storage of analytes of interest present in biological test samples (biofluid samples). In particular, the present invention relates to means to collect the biological test sample such that substantially all pathogen present in the biological test sample is inactivated, while preserving the analyte of interest in a format to allow subsequent analysis.